About Us
COMPANY STORY
About Gelteq
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a biotechnology company that has developed Gelteq® technology, a proprietary delivery technology designed to improve how active ingredients are formulated, stabilised and absorbed by the body.
Gelteq specializes in research and development, product creation and manufacturing for partners across pharmaceutical, consumer health and animal health markets. Gelteq® technology aims to address challenges associated with conventional drug and nutrient delivery by enhancing bioavailability, improving patient compliance, and enabling precise dosing.
Gelteq holds multiple patent families that cover a range of applications for our proprietary Gelteq® technology
company Story
Our Evolution
Gelteq was founded in 2017 in Melbourne, Australia and emerged from the founder’s work as a dietitian together with Monash University’s Medicines Manufacturing Innovation Centre (MMIC) research expertise to both verify and test the scientific methodologies. The company has developed Gelteq® technology, a proprietary delivery technology designed to support how selected active ingredients are formulated, consumed, and experienced.
Research and Development continued to evolve, to expand the breadth of the delivery platform across various applications. In early 2024 the Gelteq team expanded into the purpose-built Monash Innovation Labs which is a growth and development ecosystem within Monash University. Gelteq consolidated its public listing on the Nasdaq: GELS in October 2024.
the format of the medication matters to patients and carers
At Gelteq we believe better delivery underpins better health outcomes.
MOVING FORWARD
Partners and Collaborations
Gelteq is always on the lookout for partnering and collaboration opportunities that will help accelerate a partner’s product innovation. We continuously develop new products in partnership with pharmaceutical, commercial, and academic institutions. We are also actively seeking opportunities to license existing formulations and market-ready products. The structures of these licenses can be tailored to meet our partners’ need and preferences.
